ArticleArteriosclerosis, thrombosis, and vascular biology2017
Endothelial Cell-Specific Deletion of P2Y2 Receptor Promotes Plaque Stability in Atherosclerosis-Susceptible ApoE-Null Mice.
Open access · bronzeAbstract read
In one paragraph
Article in Arteriosclerosis, thrombosis, and vascular biology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.3field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 64 citations in OpenAlex.
- The role and therapeutic potential of purinergic signaling pathway in metabolic syndrome-related atherosclerosis.Purinergic signalling · 2026Review
- Shared Risk Factors and Molecular Mechanisms Between Aortic Stenosis and Atherosclerosis: A Rationale for Therapeutic Repositioning.International journal of molecular sciences · 2025Review
- Drug-like Antagonists of P2Y Receptor Subtypes: An Update.Journal of medicinal chemistry · 2025Review
- P2YAging cell · 2025Article
- Impact of Estrogen on Purinergic Signaling in Microvascular Disease.International journal of molecular sciences · 2025Review
- How selective antagonists and genetic modification have helped characterise the expression and functions of vascular P2Y receptors.Purinergic signalling · 2025Review
- Endothelial Dysfunction in Atherosclerosis: Experimental Models and Therapeutics.Biomaterials research · 2025Review
- Dissecting and validation the biomarker of heart failure progression in patients with atherosclerosis by single-cell sequencing, bioinformatics, and machine learning.Frontiers in genetics · 2025Article
- Purinergic signaling through the P2Y2 receptor regulates osteocytes' mechanosensitivity.The Journal of cell biology · 2024Article
- Basal ATP release signals through the P2YAtherosclerosis · 2024Article
- NF1-dependent disruption of the blood-nerve-barrier is improved by blockade of P2RY14.iScience · 2024Article
- Design, Synthesis, and Evaluation of a New Chemotype Fluorescent Ligand for the P2YACS medicinal chemistry letters · 2024Article
- Purinergic P2Y2 receptor-induced activation of endothelial TRPV4 channels mediates lung ischemia-reperfusion injury.Science signaling · 2023Article
- NTPDase1/CD39 Ectonucleotidase Is Necessary for Normal Arterial Diameter Adaptation to Flow.International journal of molecular sciences · 2023Article
- P2Y2 receptor decreases blood pressure by inhibiting ENaC.JCI insight · 2023Article
- Therapeutic potential for P2YPurinergic signalling · 2023Review
- Cross-Sectional Gene-Smoking Interaction Analysis in Relation to Subclinical Atherosclerosis-Results From the IMPROVE Study.Circulation. Genomic and precision medicine · 2023Article
- Purinergic receptors mediate endothelial dysfunction and participate in atherosclerosis.Purinergic signalling · 2023Review
- The Pleiotropic Role of Extracellular ATP in Myocardial Remodelling.Molecules (Basel, Switzerland) · 2023Review
- The Correlation between Increased Expressions of NLRP3 Inflammasome Components in Peripheral Blood Mono-Nuclear Cells and Plaque Vulnerability in Human Carotid Atherosclerosis.Iranian journal of public health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Xingjuan ChenFrom the Department of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis (X.C., S.Q., A.H., H.T., A.G.O., P.B.H., C.I.S.); and Department of Medicine, University of Wisconsin-Madison (T.A.H.).
Shaomin QianFrom the Department of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis (X.C., S.Q., A.H., H.T., A.G.O., P.B.H., C.I.S.); and Department of Medicine, University of Wisconsin-Madison (T.A.H.).
April HoggattFrom the Department of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis (X.C., S.Q., A.H., H.T., A.G.O., P.B.H., C.I.S.); and Department of Medicine, University of Wisconsin-Madison (T.A.H.).
Hongying TangFrom the Department of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis (X.C., S.Q., A.H., H.T., A.G.O., P.B.H., C.I.S.); and Department of Medicine, University of Wisconsin-Madison (T.A.H.).
Timothy A HackerFrom the Department of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis (X.C., S.Q., A.H., H.T., A.G.O., P.B.H., C.I.S.); and Department of Medicine, University of Wisconsin-Madison (T.A.H.).
Alexander G ObukhovFrom the Department of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis (X.C., S.Q., A.H., H.T., A.G.O., P.B.H., C.I.S.); and Department of Medicine, University of Wisconsin-Madison (T.A.H.).
Paul B HerringFrom the Department of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis (X.C., S.Q., A.H., H.T., A.G.O., P.B.H., C.I.S.); and Department of Medicine, University of Wisconsin-Madison (T.A.H.).
Cheikh I SeyeFrom the Department of Cellular & Integrative Physiology, Indiana University School of Medicine, Indianapolis (X.C., S.Q., A.H., H.T., A.G.O., P.B.H., C.I.S.); and Department of Medicine, University of Wisconsin-Madison (T.A.H.). cseye@iu.edu.
University of Wisconsin–Madison · US
Funding
TRPC Channels in the Metabolic SyndromeR01HL115140 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI OBUKHOV, ALEXANDER G. · 2012 to 2016
$2.6MExploring the contribution of a nucleotide receptor to atherosclerosisR01HL112883 · NHLBI · INDIANA UNIVERSITY INDIANAPOLIS · PI SEYE, CHEIKH IBRA · 2013 to 2017
$1.9MNHLBI NIH HHS R01 HL112883NHLBI NIH HHS R01 HL115140
Abstract
objectiveNucleotide P2Y APPROACH AND
resultsEC-specific P2Y
conclusionsEC-specific P2Y
Indexed as
Plaque, AtheroscleroticAnimalsAorta, ThoracicAortic DiseasesApolipoproteins EAtherosclerosisCell MovementCells, CulturedCollagenDisease Models, AnimalDisease ProgressionEndothelial CellsFibrosisMacrophagesMaleMatrix Metalloproteinase 2Apolipoproteins ECollagenMatrix Metalloproteinase 2Mmp2 protein, mouseNitric OxideNitric Oxide Synthase Type IIINos3 protein, mouseP2ry2 protein, mousePurinergic P2Y Receptor AgonistsReceptors, Purinergic P2Y2Vasodilator Agentsadenosine 5’-trisphosphateatherosclerosisendothelial cellreceptorsmooth muscle cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.